Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple. Growing Optimism About ProQR Therapeutics N.V. (PRQR)’s RNA Editing Platform and Future Clinical Catalysts As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR), with 100% maintaining “Buy” ratings. The consensus price target of $9.44 implies a 448.56% upside, reflecting growing optimism about the company’s RNA editing platform and future clinical catalysts. ...